Ovrian cancer
Conditions
Interventions
experimental group:NK cells therapy
Sponsors
The First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with high grade ovarian serous carcinoma, endometrioid carcinoma, primary peritoneal carcinoma and fallopian tube carcinoma; 2. Patients with platinum resistant or refractory ovarian cancer (patients who relapse within 6 months after platinum based first-line treatment or patients with disease progression during first-line treatment); 3. Patients aged 18-75 years (>= 18, = 3 x 10^9/L, ANC >= 1.5 x 10^9/L, Hb >= 90g/L, PLT >= 90 x 10^9/L; Heart: no arrhythmia, LVEF >= 50% and no pericardial effusion; Liver: liver function 50 ml / min; The oxygen saturation of fingertip in the room was more than 92%; 7. Patients without intestinal obstruction within two months (only patients receiving abdominal reinfusion); 8. All patients and donors are willing to join the clinical trial and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who plan to use targeted drugs such as PARP inhibitors and antiangiogenesis inhibitors or other immune drugs such as PD-1 / PD-L1 monoclonal antibody for maintenance treatment; 2. Patients with a history of other malignancies with a disease-free period of less than 5 years (except cured basal cell carcinoma of skin, cured carcinoma in situ of cervix, and digestive tract tumor confirmed to be cured by endoscopic mucosal resection); 3. Patients with brain metastases (unless the researchers believe that the brain metastases have been controlled and stable, it is generally not recommended to join the group); 4. Patients who have received organ transplantation; 5. Patients with allergy to biological agents used in this treatment; 6. Patients with active infection (including intraperitoneal infection); 7. HBV carriers; 8. Patients who received excessive dose radiotherapy for lung and liver within 4 months; 9. Patients with interstitial pneumonia; 10. Patients with severe autoimmune diseases; 11. Patients who were considered unsuitable for the trial by the researchers; 12. Patients with severe abdominal adhesion (only those who received abdominal reinfusion).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The patient safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics in vivo;Effectiveness; | — |
Countries
China
Contacts
Public ContactWeidong Zhao
The First Affiliated Hospital of University of science and technology of China, Anhui Provincial Hospital
Outcome results
None listed